Source: PR Newswire — 2026-07-15
Summary
TytoCare named Adam Pellegrini — previously an executive at Included Health — as CEO and closed a $25M+ growth round led by Insight Partners, with participation from HOOP, OliveTree, OrbiMed, Qumra Capital, and Qualcomm Ventures. The funding and leadership change are aimed at repositioning TytoCare, known for its handheld remote-exam device with FDA-cleared AI diagnostic algorithms, as an "AI-first clinical enablement platform" targeting chronic and complex disease management — with named focus areas including congestive heart failure, COPD, post-surgical recovery, and oncology treatment monitoring.
Key Takeaways
- New CEO Adam Pellegrini spent over two decades across digital health, consumer health tech, and large-scale clinical programs, most recently at Included Health — the appointment signals a pivot from device-company roots toward enterprise clinical-program delivery.
- The $25M+ round was led by Insight Partners with HOOP, OliveTree, OrbiMed, Qumra Capital, and Qualcomm Ventures participating — a syndicate weighted toward growth/digital-health investors rather than new strategic entrants.
- TytoCare's underlying platform combines a handheld exam device (FDA-cleared to capture heart, lung, ear, skin, throat, and abdomen data) with a suite of separately FDA-cleared AI-powered SaMD (Software as a Medical Device) algorithms that let clinicians run remote physical exams.
- The stated expansion targets specific chronic-disease programs — CHF, COPD, post-surgical recovery, and oncology treatment monitoring — through deeper integrations with health systems, payers, and employer health plans, rather than a general-purpose telehealth pitch.
- No usage metrics, clinical outcome data, or accuracy figures for the AI algorithms were disclosed in the announcement, which is a leadership-and-funding story rather than one with a verifiable performance number.